(NASDAQ: MTVA) Metavia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.93%.
Metavia's earnings in 2024 is -$27,733,000.On average, 2 Wall Street analysts forecast MTVA's earnings for 2024 to be -$33,645,519, with the lowest MTVA earnings forecast at -$34,550,200, and the highest MTVA earnings forecast at -$32,740,838. On average, 2 Wall Street analysts forecast MTVA's earnings for 2025 to be -$11,416,213, with the lowest MTVA earnings forecast at -$11,890,094, and the highest MTVA earnings forecast at -$10,942,333.
In 2026, MTVA is forecast to generate -$9,908,412 in earnings, with the lowest earnings forecast at -$9,908,412 and the highest earnings forecast at -$9,908,412.